相关实验视频
Updated: Jul 17, 2025

23:53
Ole Isacson: Development of New Therapies for Parkinson's Disease
Published on: April 29, 2007
8.0K
针对帕金森病患者的当前和新型输液疗法
Angelo Antonini1,2, Valentina D'Onofrio3, Andrea Guerra4,3
1Parkinson and Movement Disorders Unit, Centre for Rare Neurological Diseases (ERN-RND), Department of Neuroscience, University of Padua, Via Giustiniani 3, 35121, Padua, Italy. angelo.antonini@unipd.it.
Journal of neural transmission (Vienna, Austria : 1996)
|September 6, 2023
概括
先进的帕金森病管理正在通过新的药物输送系统得到改善. 这些疗法绕过了吸收问题,为晚期疾病患者提供了对运动症状的更好控制.
科学领域:
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
- 生物医学工程 生物医学工程
背景情况:
- 晚期帕金森病 (PD) 呈现出运动波动和功能衰退,尽管口服利沃多巴和辅助疗法.
- 口服乐伏多巴的吸收不一致,导致晚期PD的运动并发症.
- 现有的设备辅助疗法,如皮下阿波莫尔芬和莱沃多巴/卡比多巴阴茎输液,提供了经过验证的好处.
研究的目的:
- 审查晚期帕金森病药物输送系统的最新进展.
- 突出新的配方及其在管理运动并发症方面的潜力.
- 讨论PD管理中设备辅助疗法的未来方向.
主要方法:
- 审查当前文献和最近批准/开发的药物输送系统,用于晚期PD.
- 分析包括勒沃多巴/卡比多巴输液凝与恩塔卡在内的配方.
- 检查使用便携式的皮下输送系统 (ND0612,ABBV-951).
主要成果:
- 新配方,包括levodopa/carbidopa/entacapone凝,旨在减少levodopa的剂量.
- 皮下输送系统 (ND0612,ABBV-951) 提供连续的药物管理.
- 在ABBV-951中,使用福斯利沃多巴/福斯卡比多巴前药物,以提高吸收和耐受性.
- 这两种系统都显示出对运动并发症的有效改善.
结论:
- 新型药物输送系统显著改善了晚期帕金森病的运动并发症.
- 这些疗法通过克服口服乐伏多巴吸收变异性,提供了扩展的治疗选择.
- 未来的重点应该是早期的患者鉴定,增加转诊,以及这些治疗方法的全球可访问性.
相关概念视频
Parkinson's Disease: Treatment
295
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
295
Parkinson's Disease: Overview
593
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
593
Heart Failure VI: Adjunct Therapies
16
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
16
Drug Delivery: Parenteral Route
608
The parenteral route is a critical method of drug administration. It delivers compounds directly into the systemic circulation and bypasses the gastrointestinal tract. This approach is particularly advantageous for drugs that exhibit poor absorption or instability when administered orally.
There are three primary parenteral routes: intravenous (IV), intramuscular (IM), and subcutaneous (SC). The IV route introduces the drug directly into the bloodstream, ensuring immediate action. The IM route...
There are three primary parenteral routes: intravenous (IV), intramuscular (IM), and subcutaneous (SC). The IV route introduces the drug directly into the bloodstream, ensuring immediate action. The IM route...
608
EPS and iPS Cells in Disease Research
2.8K
Embryonic and induced pluripotent stem cells are excellent models for disease research because of their ability to self-renew and differentiate into most cell types. Somatic cells from a patient are isolated and reprogrammed into induced pluripotent stem cells or iPSCs. These iPSCs are later differentiated into the desired cell type, which mirrors the diseased cell of the patient. In this way, disease models have been created for investigating diseases such as Down syndrome, type I diabetes,...
2.8K
Peritoneal Dialysis I: Introduction and Procedure
55
Peritoneal dialysis (PD) is a procedure that facilitates the exchange of solutes, waste products, electrolytes, and excess fluid between the blood in the peritoneal capillaries and a dialysis solution introduced into the peritoneal cavity.Principles of Peritoneal Dialysis (PD)Diffusion: Waste products such as urea and electrolytes move from high concentrations in the blood to low concentrations in the dialysate across the peritoneal membrane. This mechanism is driven by the concentration...
55

